Biotech
-
Biotech VCs Move Upstream in China’s Scientific Pipelines as Competition Grows Fiercer
The following excerpt was taken from STAT News—continue reading here. U.S. venture capital firms are no longer waiting for Chinese biotech assets to surface before investing in them — they’re moving upstream, embedding themselves inside labs and courting scientists before they publish their research. In some cases, they’re vying against Chinese VCs urging scientists not to
-
Formation Bio Licenses Phase 1-Ready CNS Penetrant TYK2 Inhibitor from Lynk Pharmaceuticals
The following excerpt was taken from PR Newswire– continue reading here. NEW YORK, Dec. 10, 2025 /PRNewswire/ — Formation Bio and Lynk Pharmaceuticals today announced Formation Bio’s acquisition of worldwide rights, excluding Greater China, to LNK01006, a next generation central nervous system (CNS)–penetrant highly selective TYK2 inhibitor. The asset will be developed within Formation’s newly formed subsidiary Bleecker Bio. LNK01006